
It is normal for viruses to change and evolve as they spread between people over time. When these changes become significantly different from the original virus, they are known as “variants.” To identify variants, scientists map the genetic material of viruses (known as sequencing) and then look for differences between them to see if they have changed.
Since the SARS-CoV-2 virus, the virus that causes COVID-19, has been spreading globally, variants have emerged and been identified in many countries around the world.
A variant is considered a variant of interest if it has mutations that are suspected or known to cause significant changes, and is circulating widely (e.g., known to cause many clusters of infected people, or found in many countries). There are many variants of interest that WHO is continuing to monitor in case they become variants of concern.
A variant of interest becomes a variant of concern if it is known to spread more easily, cause more severe disease, escape the body’s immune response, change clinical presentation, or decrease effectiveness of known tools – such as public health measures, diagnostics, treatments and vaccines.
For the purpose of discussing variants in the media and the public, WHO began using the Greek alphabet in May of 2021 to make it easier for people to keep track of variants without linking their names to the places where they were first identified, as variants can emerge anywhere at any time.
In accordance with WHO best practices for naming new diseases, some letters may not be used if they cause confusion in major languages or stigmatize certain groups. These WHO labels do not replace the existing scientific names of the variants, which convey important scientific information to researchers and scientists.
The Omicron variant, variant B.1.1.529, was first reported to WHO on 24 November 2021 and was classified as a variant of concern by WHO on 26 November 2021. The classification was made on the advice of the Technical Advisory Group on Virus Evolution, based primarily on information from South Africa that the variant has a large number of mutations and has caused a detrimental change in COVID-19 epidemiology.
All variants are different. The Omicron variant has a large number of mutations which may mean the virus acts differently from other variants that are circulating.
As of 1 December 2021, there is limited information about Omicron. Studies are ongoing to determine if there is a change in how easily the virus spreads or the severity of disease it causes, and if there are any impacts on protective measures.
It will likely take time before there will be clear evidence to determine if there is any change in the transmission of Omicron compared to other variants, how the variant responds to existing therapeutics, or whether infection or re-infection with Omicron causes more or less severe disease.
WHO is working with technical partners to understand the potential impact of Omicron on vaccine effectiveness. Currently, the Delta variant is dominant worldwide and COVID-19 vaccines are highly effective at protecting you from serious illness and death, including from infection with Delta. Researchers will assess the performance of current vaccines against Omicron and will communicate these findings as soon as they become available.
See the announcement and short video on the classification of the Omicron variant.
WHO continues to coordinate with a large number of researchers around the world to understand more about all variants of SARS-CoV-2, the virus that causes COVID-19, including Omicron. Many studies are needed, including assessments of:
Transmissibility, or ease of spread from person to person, of Omicron as compared to other variants
Severity of infection and re-infection with Omicron
Performance of current COVID-19 vaccines against Omicron
Performance of diagnostic tests, including antigen tests, to detect infection with Omicron
Effectiveness of current treatments for management of patients with COVID-19 disease
WHO’s Technical Advisory Group on Virus Evolution will continue to monitor and evaluate the data as it becomes available and assess if mutations in the Omicron variant alter the behaviour of the virus.




Comments
There are no comments for this story
Be the first to respond and start the conversation.